IRIS
RISITANO, ANTONIO MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.556
NA - Nord America 2.375
AS - Asia 1.954
SA - Sud America 282
AF - Africa 56
Continente sconosciuto - Info sul continente non disponibili 3
Totale 7.226
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.234
RU - Federazione Russa 1.506
SG - Singapore 941
HK - Hong Kong 457
IT - Italia 372
CN - Cina 371
BR - Brasile 262
FI - Finlandia 133
CA - Canada 123
NL - Olanda 120
DE - Germania 100
IE - Irlanda 89
VN - Vietnam 84
GB - Regno Unito 53
FR - Francia 51
UA - Ucraina 45
IN - India 33
CI - Costa d'Avorio 32
SE - Svezia 30
AT - Austria 14
ZA - Sudafrica 14
MX - Messico 13
KR - Corea 12
JP - Giappone 10
LT - Lituania 9
TR - Turchia 9
AR - Argentina 7
BE - Belgio 7
BD - Bangladesh 5
ES - Italia 5
IQ - Iraq 4
PL - Polonia 4
PS - Palestinian Territory 4
UZ - Uzbekistan 4
VE - Venezuela 4
EG - Egitto 3
EU - Europa 3
NG - Nigeria 3
PK - Pakistan 3
AE - Emirati Arabi Uniti 2
BB - Barbados 2
CH - Svizzera 2
CZ - Repubblica Ceca 2
GR - Grecia 2
ID - Indonesia 2
IL - Israele 2
JM - Giamaica 2
KE - Kenya 2
OM - Oman 2
PE - Perù 2
PH - Filippine 2
RO - Romania 2
UY - Uruguay 2
AL - Albania 1
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
CL - Cile 1
CO - Colombia 1
DZ - Algeria 1
EC - Ecuador 1
HU - Ungheria 1
IM - Isola di Man 1
JO - Giordania 1
KZ - Kazakistan 1
LB - Libano 1
LU - Lussemburgo 1
ME - Montenegro 1
MY - Malesia 1
NO - Norvegia 1
NP - Nepal 1
PA - Panama 1
PY - Paraguay 1
QA - Qatar 1
RS - Serbia 1
SA - Arabia Saudita 1
SI - Slovenia 1
TN - Tunisia 1
Totale 7.226
Salva come PNG Salva come JPEG
Città #
Singapore 528
Hong Kong 455
Moscow 390
Chandler 346
Millbury 171
Santa Clara 145
Princeton 133
Boston 127
Nanjing 125
Des Moines 116
Amsterdam 102
Ottawa 100
Dong Ket 84
Naples 83
Ashburn 70
Napoli 70
Beijing 55
Lawrence 46
Wilmington 41
Jacksonville 36
Shenyang 36
Seattle 30
Nanchang 29
Hebei 26
Tianjin 24
Hefei 18
Helsinki 18
Jiaxing 18
Milan 17
São Paulo 17
Nuremberg 16
Ann Arbor 15
Falkenstein 15
Frankfurt am Main 15
Munich 14
Turku 14
Redwood City 13
Woodbridge 13
Rome 12
Changsha 11
Los Angeles 11
New York 11
Seoul 11
London 10
Brasília 8
Norwalk 8
Brooklyn 7
Canterbury 7
Latronico 7
Mexico City 7
Montreal 7
Mountain View 7
Stockholm 7
Brussels 6
Kochi 6
Belo Horizonte 5
Dalmine 5
New Delhi 5
Toronto 5
Atlanta 4
Bexley 4
Campinas 4
Crispano 4
Curitiba 4
Florianópolis 4
Hyderabad 4
Istanbul 4
Kronberg 4
Madrid 4
Pune 4
Rio de Janeiro 4
San Francisco 4
Sorocaba 4
Tampa 4
Tashkent 4
Vienna 4
Americana 3
Ankara 3
Boardman 3
Chennai 3
Columbus 3
Dallas 3
Dublin 3
Engelskirchen 3
Fairfield 3
Falls Church 3
Fremont 3
Hamilton 3
Indiana 3
Juiz de Fora 3
Kunming 3
Laferrere 3
Lagos 3
Manassas 3
Nocera Inferiore 3
Oleggio 3
Potenza 3
San Mateo 3
Santos 3
Taranto 3
Totale 3.874
Salva come PNG Salva come JPEG
Nome #
Narrative Based Medicine as a tool for needs assessment of patients undergoing hematopoietic stem cell transplantation 89
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial 87
Eltrombopag for post-transplant cytopenias due to poor graft function 87
(Auto-)immune signature in aplastic anemia 85
Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia after Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey 80
LONG-TERM FOLLOW UP OF ALENTUZUMAB-BASED IMMUNOSUPPRESSION FOR THE TREATMENT OF IMMUNE-MEDIATED BONE MARROW FAILURE SYNDROMES 75
ALEMTUZUMAB FOR APLASTIC ANEMIA AND RELATED IMMUNE-MEDIATED BONE MARROW FAILURES: LONG-TERM FOLLOW UP OF A PILOT STUDY 75
Acute immune toxicity during anti-thymocyte globulin: That's CARPA! 74
Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for proximal complement inhibition? A position paper from the SAAWP of the EBMT 72
Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study 71
Long-lasting bone damage detected by dual-energy x-ray absorptiometry,phalangeal osteosonogrammetry, and in vitro growth of marrow stromal cells after allogeneic stem cell transplantation 70
Excellent outcome of concomitant intensive immunosuppression and eculizumab in aplastic anemia/paroxysmal nocturnal hemoglobinuria syndrome. 70
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia 69
CIRCULATING MEGAKARYOCYTE-DERIVED CELLS DETECTED BY FLOW CYTOMETRY AS MARKER OF AGGRESSIVE NEOPLASM OF MEGAKARYOCYTIC LINEAGE IN ACUTE MEGAKARYOBLASTIC LEUKEMIA AND ALLIED MALIGNANCIES PRESENTING AS PRIMARY MYELOFIBROSIS 69
Diagnostic issues faced by a rare disease healthcare network during Covid-19 outbreak: data from the Campania Rare Disease Registry 68
Paroxysmal Nocturnal Hemoglobinuria: significant association with specific HLA-A, B, C and DR alleles in Italian patients 68
Killer Immunoglobulin-like Receptors (KIR) and their HLA-ligands in Italian Paroxysmal Nocturnal Haemoglobinuria (PNH) patients 68
PEGYLATED-FILGRASTIM AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION: SINGLE CENTRE EXPERIENCE 68
PEG-FILGRASTIM AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION : A SINGLE-CENTRE EXPERIENCE 68
Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future 68
New perspectives on the use of nucleic acids in pharmacological applications: inhibitory action of extracellular self-DNA in biological systems 66
Antilymphocyte globulin for prevention of chronic graft-versus-host disease 66
Twenty years of the Italian Fanconi Anemia Registry: Where we stand and what remains to be learned 65
Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions 62
Retroperitoneal extramedullary relapse after blinatumomab in acute lymphoblastic leukemia failing haplo-identical bone marrow transplantation. 62
THIOTEPA AND MELPHALAN AS NEW CONDITIONING REGIMEN FOR AUTOLOGOUS TRANSPLANTATION IN MULTIPLE LYELOMA 60
Network references for rare diseases: state of the art for the paroxysmal nocturnal hemoglobinuria 60
Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria 60
Acute lymphoblastic leukemia in the context of a disorder resembling X-linked lymphoproliferative (XLP) syndrome 59
XM02 PLUS CHEMOTHERAPY IS SAFE AND EFFECTIVE IN STEM CELL MOBILIZATION FOR PATIENTS CANDIDATED TO AUTOLOGOUS STEM CELL TRANSPLANTATION 59
Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High Dose Cyclophosphamide 59
Eculizumab treatment modifies the immune profile of PNH patients. 58
CHRONIC GRAFT Vs HOST DISEASE OF THE GENITAL TRACT: DIAGNOSIS, CLINICAL IMPACT AND MANAGEMENT FROM SURVEILLANCE PROGRAM IN A PRELIMINARY COHORT 58
Expression of the 67-kDa laminin receptor in acute myeloid leukemia cells mediates adhesion to laminin and is frequently associated with monocytic differentiation. 57
Expression of the 67-kDa laminin receptor in acute myeloid leukemia cells mediates adhesion to laminin and is frequently associated with monocytic differentiation. 56
Transplant results in adults with Fanconi anaemia 56
Oral dysplastic complications after HSCT: Single case series of multidisciplinary evaluation of 80 patients 56
Factor H interfers with the adhesion of sickle red cells to vascular endothelium: a novel disease modulating molecule 55
Aplastic anemia: immunosuppression. Current challenges and future goals in immunosuppression for aplastic anemia. 54
Epidemiology of Acquired Bone Marrow Failure 54
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 54
Complete remission induced by high dose erythropoietin and granulocyte colony stimulating factor in acute erythroleukemia (AML-M6 with maturation) 52
Role of the Urokinase Receptor (uPaR) in the cross-talk of hematopoietic Stem Cells with the bone marrow environment 52
Alternative immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: Campath (Alemtuzumab). 51
Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: A retrospective analysis 51
Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. 50
Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia. 50
Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT group 49
Bone Marrow of Contention: A Rare Case of Recurrent Acute Hepatitis 49
Aplastic Anemia & MDS International Foundation (AA&MDSIF): Bone Marrow Failure Disease Scientific Symposium 2010 Meeting Report. 47
T cell receptor VB repertoire diversity in patients with immune thrombocytopenia following splenectomy. 47
Veno-occlusive Disease in HSCT Patients: Consensus-based Recommendations for Risk Assessment, Diagnosis, and Management by the GITMO Group 47
Therapeutic complement modulation for hematological diseases: Where we stand and where we are going 46
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: The 302 study 46
Paroxysmal nocturnal hemoglobinuria: significant association with specific HLA-A, -B, -C, and -DR alleles in an Italian population. 45
A pilot study of the recombinant soluble human tumor necrosis factor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. 44
Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anemia and single-lineage marrow failure: a pilot study and a survey from EBMT WPSAA. 44
Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life. 42
Selective reduction of natural killer T cells in the bone marrow of aplastic anaemia. 42
Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. 42
Aplastic anemia: immunosuppressive therapy in 2010. 42
Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies 42
Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients 41
The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target 41
Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3. 41
CD34+ cells from Paroxysmal Nocturnal Hemoglobinuria (PNH) patients are deficient in surface expression of cellular prion protein (PrPc). 41
Aplastic Anemia: Alternative Immunosuppressive Treatments and Eltrombopag. A report from the 2014 EBMT Educational Meeting from the Severe Aplastic Anaemia and Infectious Diseases Working Parties 41
Stem cell transplantation for congenital dyserythropoietic anemia. An analysis from the European society for blood and marrow transplantation 41
Easy genotyping of complement C3 'slow' and 'fast' allotypes by tetra-primer amplification refractory mutation system PCR. 40
Application of the molecular analsysis of the T –cell receptor repertoire in the study of immune-mediated hematologic disease. 40
Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients 39
Advances in understanding the pathogenesis of acquired aplastic anaemia 39
Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls 38
Long lasting decrease of marrow and circulating long-term culture initiating cells after allogeneic bone marrow transplant 38
Future Strategies of Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria 38
Shared And Individual Specificities Of Immunodominant Cytotoxic T Cell Clones In Paroxysmal Nocturnal Hemoglobinuria As Determined By Molecular Analysis. 38
Small-molecule factor D inhibitors targeting the alternative complement pathway 38
Steroid treatment of acute graft-versus-host disease grade I: A randomized trial 38
Allogeneic stem cell transplantation for acquired pure red cell aplasia 38
Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow Transplantation 37
Aplastic anemia: management of adult patients. 37
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. 37
Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: A prospective study of the gruppo italiano trapianto midollo osseo (GITMO) 37
Role of the Urokinase Receptor (uPAR) in the Cross-Talk of Hematopoietic Stem Cells with the Bone Marrow Microenvironment 36
Retrospective survey on the prevalence and outcome of prior autoimmune diseases in patients with aplastic anemia reported to the registry of the European group for blood and marrow transplantation. 36
Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria 36
Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita 36
Activated platelets of patients with paroxysmal nocturnal hemoglobinuria express cellular prion protein (PrPc). 35
Transcript profile of CD4+ and CD8+ T cells from the bone marrow of acquired aplastic anemia patients. 35
New challenges to developing animal models for human immune-mediated marrow failure. 35
Should irradiated blood products be given routinely to all patients with aplastic anaemia undergoing immunosuppressive therapy with antithymocyte globulin (ATG)? A survey from the European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. 35
Use of eltrombopag in aplastic anemia in Europe 35
The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. 34
Bone marrow versus peripheral blood sibling transplants in acquired aplastic anemia: survival advantage for marrow in all age groups. 34
Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going 34
Immune insights into AA 34
Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party 34
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria 34
Paroxysmal nocturnal hemoglobinuria and other complement-mediated haematological disorders. Immunobiology. 33
The relationship of aplastic anemia and PNH. 33
Totale 5.104
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.732
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.732
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202050 0 0 0 0 0 0 0 0 0 0 0 50
2020/2021303 52 14 13 9 36 25 12 3 25 2 23 89
2021/2022816 2 1 2 1 3 26 7 42 96 42 151 443
2022/2023911 191 79 18 33 106 97 9 107 128 90 44 9
2023/2024601 10 107 108 26 27 43 8 52 8 9 153 50
2024/20253.965 246 241 15 37 60 153 506 264 430 449 1.412 152
Totale 7.472